Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_2
4
57%
Ph phase_1
3
43%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
57.1%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

completed457%
terminated343%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

NCT00577278
completedphase_2

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00058422
terminatedphase_1

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00012298
terminatedphase_2

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

NCT00088881
completedphase_2

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00005592
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00577278Phase 2

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Completed
NCT00058422Phase 2

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Completed
NCT00012298Phase 1

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Terminated
NCT00088881Phase 2

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Terminated
NCT00005592Phase 2

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
NCT00064246Phase 1

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Completed
NCT00036855Phase 1

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Terminated

All 7 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
7